���񱦵�

When Brian DeDecker drives past the bucolic green soybean fields en route to his childhood home in rural Illinois, his mind drifts not to the past but to the future.

As a first-generation college student turned molecular biologist, DeDecker imagines a day when these humble beans, which his family has grown for generations, pack a bounty of therapeutic but hard-to-obtain natural compounds.

Some will be loaded with chemotherapy drugs typically stripped from old growth trees. Others will burst with vaccine additives, now mainly accessed by harvesting the livers of endangered sharks or immune-boosting proteins accessible only through human breast milk.

“Since the discovery of DNA in the 1950s, we have amassed an amazing amount of knowledge about how biology works at the molecular level,” said DeDecker, a teaching associate professor in the Department of Molecular, Cellular and Developmental Biology at ���񱦵�. “We are now in a position to use that knowledge to actually build new life—to engineer organisms to do new things that can address some of the world’s biggest problems.”

In recent years, DeDecker and former student Simon Kalmus have put that vision into action, working with members of CU’s iGEM (International Genetically Engineered Machine) student research team to devise a magic bean of sorts—one that can shapeshift into a custom-made chemical factory depending on what genetic instructions they give it.

Their new company  is among a host of startups sprouting from the burgeoning field of synthetic biology, a $9 billion and growing industry combining the ancient wisdom of evolution with cutting-edge genetic engineering tools. Many companies already genetically program microorganisms to churn out desired chemicals. For instance, insulin, which was once harvested from dog pancreases, is now produced by heaping vats of yeast and bacteria.

But there’s a hitch:

“You have to feed yeast and bacteria plants in order to make the chemicals. We make it directly in plants,” said DeDecker, whose company will begin producing bean-borne protein supplements for baby formula this spring. “Someday, there could be soybean fields across the Midwest dedicated to biopharming.”

Endangered sharks and old growth trees

Teaching Associate Professor Brian DeDecker and his students (in lab coats) check out some soybean samples. From left are Maya Nelson, a biochemistry and public health major; Lindsey Neukirch, an MCDB and public health major; and David Birkhaeuser, an MCDB and Spanish major. Photo by Casey A. Cass/���񱦵�.

Kalmus, a Colorado-raised prodigy, left high school early and spent a few years farming in southern France before enrolling in the Department of Chemical and Biological Engineering at ���񱦵�. He was drawn to the promise of synthetic biology and eagerly joined the iGEM team. One day, DeDecker came into the lab excited about the potential of bioengineering plants. Soon after, Kalmus wandered into DeDecker’s office excited to share his own ideas about how to do it.

“Over the course of a month or two we went from, ““Huh. This is a fun idea,’ to realizing it might actually work,” recalled Kalmus, who graduated in 2019 and has stayed on as a research associate and company co-founder.

As plants go, he explained, soybeans are remarkably efficient, turning the sun’s energy into a cornucopia of proteins and fats while restoring nitrogen to the soil rather than stripping it as many crops do. Because it is cheap and nutritionally dense, it’s used broadly as feedstock for cattle.

It’s also possible to infuse the beans with the genetic blueprint to build something more scarce: the natural oil squalene. The oil is widely used to strengthen vaccines and keep skin and lips supple in cosmetics. But it’s primarily sourced from the livers of sharks. The oil helps them stay buoyant.

“We are decimating shark populations for this and we don’t need to be,” said DeDecker.

Taxol, or paclitaxel, a widely used chemotherapy treatment, comes from the bark of yew trees, which use it to fight off wood-degrading fungi. But as the old growth giants have grown increasingly endangered, environmentalists have become concerned.

Enter DeDecker’s students.

Where scientists used to have to tromp through the forest, get a sample and analyze it to understand the tree’s genetic code, they can now order yew DNA from a commercial vendor and play around with it in the lab.

In time, they developed a platform for infusing an otherwise normal soybean plant with the genetic instructions to, when switched on, produce taxadiene—the first step in synthesizing the anti-cancer drug paclitaxel (Taxol).

To switch it on, they essentially make bean soup.

“At the end of the day, you essentially add water to a big pot of beans, let them sit and they start to putter away making whatever it is that you want them to make,” said Kalmus.